🇺🇸 FDA
Patent

US 9868698

(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid

granted A61KA61K31/216A61K45/06

Quick answer

US patent 9868698 ((2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid) held by Theravance Biopharma R&D IP, LLC expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/216, A61K45/06, A61K9/0019, A61K9/0075